Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lutetium Lu 177 vipivotide tetraxetan

(loo-TEE-shee-um … vy-PIH-voh-tide teh-TRAK-seh-tan)
A radioactive drug used to treat adults with PSMA-positive prostate cancer that has spread to other parts of the body and has not responded to treatments that lower testosterone levels. It is used in patients whose cancer has been treated with an androgen receptor inhibitor and who can either delay or have received treatment with a type of anticancer drug called a taxane. Lutetium Lu 177 vipivotide tetraxetan binds to a protein called PSMA, which is found on some prostate cancer cells. It gives off radiation that may kill the cancer cells. Lutetium Lu 177 vipivotide tetraxetan is a type of radioconjugate. Also called Pluvicto.
More Information
Search NCI's Dictionary of Cancer Terms